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Protein phosphorylation plays a cardinal role in regulating 
many cellular processes in eukaryotes. In particular, pro- 
tein phosphorylation is a major currency of signal trans- 
duction pathways. Processes that are reversibly controlled 
by protein phosphorylation require not only a protein ki- 
nase (PK) but also a protein phosphatase (PP). Target 
proteins are phosphorylated at specific sites by one or 
more PKs, and these phosphates are removed by specific 
PPs. In principle, the extent of phosphorylation at a partic- 
ular site can be regulated by changing the activity of the 
cognate PK or PP or both. The importance of PKs in regu- 
lating cellular activities is underscored by the large number 
of PK genes that are present in eukaryotic genomes. The 
latest estimate is that humans have as many as 2000 con- 
ventional PK genes (Hunter, 1994). 
The appreciation that there is also a large number of PPs 
with distinct specificities has been more recent. Indeed, 
extrapolating from the density of PP genes in the recently 
reported 2.2 Mb of chromosome lit sequence (Wilson et 
al., 1994), one can calculate that Caenorhabditis elegans 
has about 230 PP genes; about half these encode protein- 
serine/threonine phosphatases (PSPs) and the other half 
protein-tyrosine phosphatases (PTPs). Since mammals 
have about five times as many genes as C. elegans, hu- 
mans could have as many as 1000 PP genes. The idea 
that PPs act constitutively to reverse the action of regu- 
lated PKs has also proved to be a misconception. Although 
the use of PP inhibitors shows that there is significant 
basal PP activity in cells, it has become apparent hat the 
activities of PPs are regulated in a sophisticated manner 
by a combination of targeting and regulatory subunits and 
by specific inhibitors (Table 1) (reviewed by Cohen and 
Cohen, 1989; Cohen, 1992; Hubbard and Cohen, 1993; 
MacKintosh and MacKintosh, 1994; Shenolikar, 1994). 
The essential nature of PP function can be discerned 
in the yeasts, where genetic analysis has shown that the 
four major types of PSPs, namely PP1, PP2A, PP2B, and 
PP2C, are all essential genes, with the catalytic (C) subunit 
genes often being present in multiple copies. PP genes 
have also been uncovered in yeast mutant hunts; for in- 
stance, SIT4, which encodes a PPl-related C subunit, was 
identified as a suppressor of HIS4 transcription. Likewise, 
genes for the A- and B-type PP2A subunits have been 
encountered in this way: TPD3 encodes an A-type subunit 
and complements a temperature-sensitive mutation in 
transfer RNA (tRNA) synthesis, and CDC55 encodes a 
B-type subunit. PP mutations also generate phenotypes 
in higher eukaryotes, including in Drosophilathe abnormal 
anaphase resolution (aar) mutant in the PP2A B-type regu- 
latory subunit and the retinal degeneration (rdgc) mutant 
in a novel PPl/PP2A-related C subunit and in the mouse 
the motheaten mutation in the PTPIC (HCP, SH-PTP1) 
gene. The importance of PPs in cellular physiology is em- 
phasized by the fact that they are often targets for micro- 
Table 1. PPs 
Name Regulatory Subunits Inhibitors Localization 
PSPs 
PP1 
PP4 (PPX) 
PP5 
PP2A 
PP2B 
PP2C 
Dual specificity phosphatases 
Cdc25NB/C 
VH family 
MKP1 (CL100, 3CH134) 
PAC1 
PTPs 
RPTPs 
Nonreceptor PTPs 
G and M targeting Phospho-I-1; I-2; NIPP1; 
subunits high OA; tautomycin 
Low OA 
Intermediate OA 
A anc B type Low OA; SV40 small t antigen 
(for some substrates) 
B; calmodulin FK506 and 
cyclosporin 
A/immunophilin 
complexes 
Requires Mg 2÷ EDTA 
Vanadate Nuclear 
Vanadate Nuclear 
Vanadate Nuclear 
Cytoplasmic/nuclear PP1G (glycogen 
particle); PP1M (myofibrils) 
Nuclear/centrosome 
Nuclear 
Cytoplasmic/nuclear 
Cytoplasmic/nuclear 
Vanadate Plasma membrane 
Vanadate Specific locations in different 
subcellular compartments 
The nomenclature PP1 and PP2 was originally based on their specificities for the J3 and (z subunits of phosphorylase kinase, respectively. The 
PP1, PP4, PP5, PP2A, and PP2B catalytic subunits are all related, but the PP2C catalytic domain is distinct. There are multiple catalytic domain 
and regulatory subunit genes for most of these PSPs, and several other PPl-related PSPs are known. The dual specificity PP and PTP family 
catalytic domains are related to one another but distinct from all the PSP catalytic domains. 
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bial or viral intervention. For instance, the ~ bacteriophage 
encodes a PSP, the virulence plasmid of Yersinia encodes 
a PTP, and vaccinia virus encodes a dual specificity PP 
in the PTP superfamily. Papovavirus T antigens displace 
the B-type regulatory subunit of PP2A, thus altering its 
specificity; this ability of T antigens is essential for their 
transforming activity (reviewed by Mayer-Jaekel and Hem- 
mings, 1994). 
Many microbial toxins are inhibitors of PP2A, of the re- 
lated PP1, or of both. These compounds have become 
invaluable tools for investigating PSP function in vivo and 
have uncovered important roles for serine dephosphoryla- 
tion in cell physiology (reviewed by Cohen et al., 1990; 
MacKintosh and MacKintosh, 1994). For instance, okadaic 
acid (OA), a potent inhibitor of PP2A and a strong inhibitor 
of PP1 and the related PSPs, PP4 (PPX), and PP5, elicits 
phosphorylation of many proteins in unstimulated cells 
and induces diverse cellular responses, including tran- 
scriptional activation, shape changes, and a pseudomi- 
totic state. Indeed, OA was first discovered as a tumor 
promoter, and only later was it shown that instead of acti- 
vating protein kinase C, like other types of tumor promoter, 
OA acts in a novel fashion to block dephosphorylation of 
many of the proteins phosphorylated by protein kinase C. 
The response to PSP inhibitors varies from cell to cell, 
indicating that the balance of PKs and PPs is different in 
every cell type. Paradoxically, such inhibitors can stimu- 
late phosphorylation of proteins that are not targets for 
PP2A or PP1 by activating PKs that are themselves posi- 
tively regulated by phosphorylation. Another important 
class of PSP inhibitors includes the microbially derived 
immunosuppressants cyclosporin A and FK506, which 
block T cell activation through inhibition of the Ca2+-cal - 
modulin (CaM)-activated PSP called PP2B (calcineurin) 
(reviewed by Schreiber, 1992). These inhibitors act by 
binding stably to PP2B as complexes with endogenous 
binding proteins known as immunophilins. So far, there 
are no specific inhibitors of the other major class of PSP, 
PP2C. There are also two endogenous protein inhibitors 
of PP1, inhibitor 1 (I-1) and inhibitor 2 (I-2), that play an 
important role in physiological regulation of PP1 activity 
(see below). 
PKs versus PPs 
The critical, countervailing role played by protein-serine 
kinases (PSKs) and PSPs in regulating metabolism has 
been extensively reviewed (Cohen, 1992). The regulation 
of glycogen metabolism provides a particularly good ex- 
ample (Cohen, 1992; Shenolikar, 1994). Muscle glycogen 
phosphorylase, which breaks down glycogen in response 
to stimuli such as adrenalin, is activated through phos- 
phorylation at a single serine by phosphorylase kinase. 
Phosphorylase kinase is activated both by cAMP-depen- 
dent protein kinase A (PKA) phosphorylation and by Ca 2~- 
CaM, allowing dual activation by receptors that activate 
adenylyl cyclase and by receptors that increase intracellu- 
lar Ca 2+. PKA also inhibits PP1 action on phosphorylase 
in two ways. First, it phosphoryiates I-1, thus converting it 
into a state that inhibits PP1. Second, PKA phosphorylates 
the PP1 G targeting subunit, which binds to the glycogen 
particle in association with the PP1 C subunit, causing dis- 
sociation of the C subunit and its release from the glycogen 
particle. The G subunit is also phosphorylated bythe insu- 
lin-activated ISPK-1/Rsk PSK at a distinct site, which acti- 
vates the associated PP1 C subunit in response to insulin 
and provides one mechanism by which insulin inactivates 
glycogen phosphorylase. Glycogen synthase, which is in- 
hibited by adrenalin and activated by insulin treatment, is 
subject to multisite phosphorylation by as many as seven 
PKs, including PKA and multifunctional Ca2+-CaM-depen - 
dent protein kinase II (CaMKII). Phosphorylation by PKA 
or CaMKII inactivates glycogen synthase, whereas PP1 
dephosphorylation activates it. Thus, PP1 plays an essen- 
tial role in the switch from glycogen catabolism to glycogen 
synthesis induced by insulin. 
The requirement for the coordinated action of protein- 
tyrosine kinases (PTKs) and PTPs in cell signaling has 
also been recently reviewed (Sun and Tonks, 1994). PTPs 
play an important role in attenuation of signals generated 
by PTKs involved in mitogenesis. For instance, when a 
cell is stimulated by a growth factor that activates a recep- 
tor PTK (RPTK), such as platelet-derived growth factor, the 
increase in phosphotyrosine (pTyr) in the platelet-derived 
growth factor RPTK itself and in cellular proteins is tran- 
sient. The extent and duration of RPTK-mediated tyrosine 
phosphorylation can be greatly enhanced by treatment 
with the PTP inhibitor sodium orthovanadate or its peroxy 
derivatives (Gordon, 1991; Posner et al., 1994). Indeed, 
as is the case for PSP inhibitors, vanadate derivatives can 
themselves induce cellular responses in some systems, 
implying that the basal activity of PTKs is sufficient o pro- 
mote a response if constitutive PTP activity is diminished. 
Consistent with an important role in negative regulation, 
expression of nonreceptor PTPs can reverse platelet- 
derived growth factor RPTK-mediated tyrosine phosphory- 
lation and transformation by oncogenic PTKs like v-Src, 
v-Fms, and Neu. Moreover, the phenotype of the inactivat- 
ing PTPIC mutation in the motheaten mutant mouse, 
which results in deregulated myeloid cell proliferation, im- 
plies that SH2-containing PTP1C is a negative regulator 
of myeloid cell growth (Shultz et al., 1993; Tsui et al., 1993). 
In keeping with this idea, overexpression of PTP1C inhibits 
interleukin-3 (IL-3)-induced myeloid cell growth (Yi et al., 
1993). However, not all PTPs have a negative regulatory 
function. For instance, PTPID, an SH2-containing PTP 
closely related to PTP1C, and its Drosophila homolog 
corkscrew are required for RPTK signaling (Perkins et al., 
1992; Noguchi et al., 1994). Other examples of PTPs that 
can activate signaling pathways include CD45, which is 
needed for T cell signaling, and the receptor-like PTP 
RPTP(~, which transforms rat embryo fibroblasts, appar- 
ently by dephosphorylating and thus activating the c-Src 
PTK (Zheng et al., 1992). Indeed, the negative regulation 
of c-Src family PTKs by phosphorylation of a C-terminal 
tyrosine by Csk family PTKs and activation by as-yet-uniden- 
tified PTPs provides another good example of the counter- 
acting influences of PKs and PPs (Sun and Tonks, 1994). 
For a protein to be regulated by phosphorylation, the 
maximal activities of the PK(s) and PP(s) acting on a partic- 
ular site must be nearly in balance; otherwise, the protein 
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would be either fully phosphorylated or completely de- 
phosphorylated. The intrinsic catalytic activity of most 
PSPs and PSKs is approximately the same, and the intra- 
cellular concentrations of the major PSKs and PSPs are 
also similar (Cohen, 1992). In principle, this would provide 
balance, although the affinities for specific substrates, to- 
gether with the subcellular Iocalizations of both the target 
proteins and the relevant PSKs and PSPs, will also be 
paramount. In contrast, intrinsic PTP activity is generally 
two or three orders of magnitude greater than that of the 
PTKs (Sun and Tonks, 1994). This high activity can ac- 
count for the low level of pTyr in cellular proteins and for the 
transient natu re of most pTyr responses. Nevertheless, for 
PTK signaling to be effective, PTP activity must be tightly 
regulated. Two known regulatory principles for PTP activ- 
ity are discrete subcellular localization and serine/threo- 
nine or tyrosine phosphorylation (Sun and Tonks, 1994). 
However, in contrast with the PSPs, so far no PTP regula- 
tory subunits or protein inhibitors have been identified. 
Not surprisingly, aprecise balance of PK and PP activity 
plays a major role in receptor-mediated signaling path- 
ways and cell cycle control. Space constraints dictate that 
I can cover only three illustrative xamples in which PK 
and PP antagonism is paramount in signal transduction. 
MAP Kinase Pathways 
The mitogen-activated protein (MAP) kinase (MAPK) path- 
way is a conserved eukaryotic signaling module that con- 
verts receptor signals into a variety of outputs (reviewed 
by Marshall, 1995 [this issue of CeffJ; Davis, 1994). MAPK 
pathways are extensively used for transcytoplasmic sig- 
naling to the nucleus, where transcription of specific genes 
is induced through phosphorylation and activation of tran- 
scription factors. Currently, four distinct MAPK pathways 
are known in budding yeast and three in vertebrates, but 
others may yet be found. MAPKs are activated through 
threonine/tyrosine phosphorylation by a dual specificity 
PK, known as a MAPK kinase (MAPKK), which in turn is 
activated by serine phosphorylation by a third PK, known 
as MAPKK kinase (MAPKKK). 
In vertebrates the best-understood MAPK pathway 
leads to activation of the ERKI/ERK2 MAPKs (Figure 1). 
Both RPTKs and G protein-coupled serpentine receptors 
link to this pathway (reviewed by Johnson and Vaillincourt, 
1994). One established mechanism of RPTK coupling in- 
volves activation of Ras by translocation of the GRB2- 
SOS complex to the plasma membrane, as a consequence 
of its binding to an autophosphorylation site in the RPTK 
itself, or to a substrate or docking protein phosphorylated 
by the RPTK (reviewed by Schlessinger, 1994; van der 
Geer et al., 1994). Juxtaposition of SOS and Ras at the 
plasma membrane results in exchange of GDP for GTP 
on Ras. GTP-bound Ras binds to the N-terminus of Raf 
family members, which are MAPKKKs, thus bringing Raf 
to the membrane. At the membrane, an as-yet-uncharac- 
terized event occurs that activates Raf and subsequently 
results in Raf autophosphorylation. Activated Raf phos- 
phorylates and activates the cytoplasmic MEKI/MEK2 
MAPKKs, which in turn phosphorylate and activate ERKI/ 
ERK2. A fraction of the activated ERKI/ERK2 population 
translocates into the nucleus and phosphorylates tran- 
RPTK ~?{'-~,~.z:.~.~,~.~,~. Serpentine 
~ ~ ~ ~  __~:~ ~ * .%~. . , eceptor .~ j~ ~ + )  ~ '0  
gene expression 
Figure 1. ERKI/ERK2 MAPK Pathway 
A schematic llustration ofthe PKs and PPs that regulate activation 
of the ERKI/ERK2 MAPK pathway. Abbreviations ot defined in text: 
cPLA2, cytosolic phospholipase A2; TF, transcription factor• 
scription factors, such as TCF/Elkl (reviewed by Hill and 
Treisman, 1995 [this issue of Cell]). Activated ERKI/ERK2 
can also phosphorylate cytoplasmic substrates, such as 
cytosolic phospholipase A2, and activate other PSKs, 
such as Rsk, which themselves can enter the nucleus and 
phosphorylate transcription factors. 
Several of the components of the ERKI/ERK2 path- 
way are subject to regulation by PPs. The MAPKKs and 
MAPKs, and possibly Raf, are activated by phosphoryla- 
tion, and removal of the activating phosphates results in 
inactivation. The physiological PP for Raf is not known, 
although it can be dephosphorylated in vitro by PP1 and 
PP2A. The activating phosphoserines (pSers) in MEKI/ 
MEK2 can be dephosphorylated invitro by PP2A (Nakielny 
et al., 1992). PP2A also dephosphorylates the activating 
phosphothreonine (pThr-183) in ERKI/ERK2 in vitro (An- 
derson et al., 1990), and pTyr-185 can be dephosphory- 
lated by several PTPs; both phosphates can be hydrolyzed 
by MKP1 (CL100, 3CH134) and PAC1, members of the 
VH family of dual specificity PPs, which can hydrolyze 
both pSer/Thr and pTyr (Alessi et al., 1993; Sun et al., 
1993) (see below). Consistent with a role for this type of 
PP in regulating MAPK, in budding yeast, Msg5, a VH family 
PP, down-regulates the pheromone-activated MAPK path- 
way, apparently by inactivating the Fus3 MAPK (reviewed 
by Clarke, 1994). 
Which then are the physiologically important PPs in- 
volved in down-regulating the ERKI/ERK2 pathway (Fig- 
ure 1)? SV40 small t antigen, which is a surrogate B-type 
specificity subunit for PP2A, inhibits PP2A inactivation of 
MEK and ERK1 in vitro, and expression of small t antigen 
in CV1 cells results in up-regulation of MEK and ERKI/ 
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ERK2 activity, without any effect on Rafl activity (Sontag 
et al., 1993). This indicates that PP2A is an important nega- 
tive regulator, but does not reveal which component(s) is 
the target for inactivation by PP2A; MEKI/MEK2 is the 
best candidate, but ERKI/ERK2 could also be a target. 
ERKI/ERK2 can also be inactivated in vivo by the dual 
specificity PPs MKP1 and PAC1 (Sun et al., 1993; Ward 
et al., 1994). Expression of exogenous MKP1 in COS cells 
and PAC1 in COS cells or Jurkat T cells prevents activation 
of ERK2 not only by mitogens or tetradecanoyl phorbol 
acetate, but also by v-Ras and activated Raf. Interestingly, 
a catalytically inactive MKP1 serine to cysteine mutant 
also blocks ERKI/ERK2 signaling, but by a different mech- 
anism in which the activated, phosphorylated ERK2 be- 
comes stably associated with MKP1 as an abortive sub- 
strate-enzyme complex (Sun et al., 1993). MKP1 and 
PAC1, which were identified as early response genes in 
fibroblasts and T cells, respectively, are both expressed 
transiently in response to mitogenic stimuli. The kinetics 
of expression of MKP1 is consonant with it playing a role 
in the negative regulation of ERKI/ERK2 activity in fibre- 
blasts, where activation of ERKI/ERK2 by mitogens is 
maximal by 30 min and then declines, with MKP1 levels 
peaking slightly later (Sun et al., 1993). In mitogen- 
stimulated NIH 3T3 fibroblasts, inhibition of protein syn- 
thesis blocks down-regulation of ERK2 activity consistent 
with synthesis of MPK1 being required for ERKI/ERK2 
inactivation. PAC1 and MKP1 are nuclear proteins (Rohan 
et al., 1993) and are therefore positioned to inactivate ac- 
tive ERKI/ERK2 following translocation into the nucleus. 
However, MKPl-related PPs may not be important in 
ERKI/ERK2 down-regulation in all cell types. For in- 
stance, in PC12 cells, ERKI/ERK2 inactivation following 
epidermal growth factor (EGF) or nerve growth factor 
(NGF) treatment occurs normally when protein synthesis 
is inhibited (Wu et al., 1994; Alessi et al., 1995). Inactiva- 
tion of ERKI/ERK2 may be effected instead by PP2A de- 
phosphorylation of pTyr-183, leaving pTyr-185 to be de- 
phosphorylated by an unknown PTP (Alessi et al., 1995). 
MPK1 is induced by NGF and EGF in PC12 cells and 
accumulates in the nucleus, but nuclear ERKI/ERK2 re- 
mains activated in NGF-treated cells. Perhaps there is 
spatial separation of MPK1 and ERKI/ERK2, or else there 
is an MKP1 inhibitor in the nucleus. Inactivation of cyto- 
plasmic ERKI/ERK2 may usually be due to PP2A, but 
once ERKI/ERK2 enters the nucleus, it is protected from 
cytoplasmic PPs. The nature of the nuclear ERKI/ERK2 
PP(s) in cells where MKP1 is not involved is unknown; it 
could be nuclear PP2A or another PP. 
The kinetics of activation and inactivation of each com- 
ponent in the ERKI/ERK2 pathway govern the extent and 
duration of ERKI/ERK2 activation, and this in turn can 
determine the cellular response to a stimulus. For in- 
stance, the duration of the ERKI/ERK2 signal is a critical 
factor in the decision of PC12 cells to grow or differentiate 
in response to growth factors that activate RPTKs: pro- 
longed activation commits cells to differentiate, whereas 
transient activation results in cell growth (see primary ref- 
erences in Marshall, 1995). NGF induces persistent activa- 
tion of MEKI/MEK2 and ERKI/ERK2 in PC12 cells, where- 
as EGF induces only transient activation. Both cytokines 
activate ERKI/E RK2 through the G RB2-SOS-Ras-Raf- 
MEK connection, but down-regulation of the ERKI/ERK2 
pathway is less efficient in NGF-treated than in EGF- 
treated cells. In addition to PP2A-mediated dephosphory- 
lation of MEKI/MEK2 and ERKI/ERK2, there are many 
steps at which the ERKI/ERK2 pathway can in principle 
be attenuated, including RPTK down-regulation; ERKI/ 
ERK2 phosphorylation of SOS (or other RasGTP exchange 
factors or GTPase-activating proteins), MEKI/MEK2, and 
possibly a scaffolding protein; and induction of MKPI. The 
mechanism(s) underlying the slow down-regulation of 
ERKI/ERK2 in NGF-treated PC12 cells is unknown. The 
fact that activation of MEKI/MEK2 in the cytoplasm is pro- 
longed suggests that PP2A function is compromised in 
NGF-treated PC12 cells, but the key compartment is the 
nucleus, where activated ERKI/ERK2 persists. It will be 
important to characterize nuclear ERKI/ERK2 PPs in 
PC12 cells and determine whether there are NGF-induced 
inhibitors of these PPs present in the nucleus of NGF- 
treated PC12 cells. One should also bear in m ind that once 
ERKI/ERK2 is dephosphorylated in the nucleus, it has to 
exit to the cytoplasm to be reactivated, and this can only 
happen if active MEKI/MEK2 is still present. In summary, 
the kinetics of ERKI/ERK2 activation differs from cell to 
cell and from cytokine to cytokine. The relative contribu- 
tions of the different down-regulation mechanisms need 
to be known to be able to predict the kinetics of ERKI/ 
ERK2 activation in a given cell and hence to determine 
the cellular response. 
PK Cascades and Cross-Talk 
The existence of PK cascades was established over 20 
years ago with the discovery that PKA phosphorylates and 
activates phosphorylase kinase in response to elevated 
cAMP. The use of PK cascades for signal transduction 
is attractive because in principle it allows amplification, 
feedback, cross-talk, and branching. In general, multicy- 
clic enzyme cascades are superior to single enzyme sys- 
tems because they can respond to a greater number of 
regulators, can achieve a greater degree of amplification, 
and show very pronounced sigmoidal responses to stimu- 
lus intensity (Chock and Stadtman, 1977). Theoretical 
analyses of multicyclic interconvertible enzyme cascades, 
such as a PK cascade, indicate that an amplification factor 
of 100 can be achieved at each stage, although a factor 
of 10 is a more reasonable estimate. Thus, a four PK cas- 
cade, as exemplified by the ERKI/ERK2 pathway leading 
to Rsk activation (Figure 1), could generate a theoretical 
amplification of - 10,000 times. Not only can each of the 
three serial PKs in the ERKI/ERK2 pathway amplify the 
signal, but further amplification can be achieved by cata- 
lytic action of translocated GRB2-SOS complex on Ras 
at the membrane. Members of the Fus3/Kssl MAPK path- 
way assemble onto the Ste5 scaffolding protein (Choi et 
al., 1994), and this may also occur for other MAPK sys- 
tems. Depending on their stability, the assembly of such 
signaling complexes would restrict he degree of amplifica- 
tion attained in practice, although it has the virtue of lim- 
iting cross-talk between pathways. The actual amplifica- 
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tion achieved by a MAPK pathway in vivo is not yet known, 
but experimental evidence shows that binding of <5% of 
Rafl molecules to Ras is sufficient to induce maximal 
activation of ERK2 (Hallberg et al., 1994). Consistent with it 
achieving a high degree of amplification, the ERKI/ERK2 
pathway can be activated by extremely weak input signals. 
For instance, EGF binding to a kinase-inactive form of 
the EGF RPTK (EGFR) is capable of activating ERK2 with- 
out inducing any detectable autophosphorylation of the 
EGFR (Campos-Gonzalez and Glenney, 1992; Selva et al., 
1993). Presumably, this occurs through EGF-induced di- 
merization of the mutant EGFR with other members of the 
EGFR family present in the same cell, such as ErbB2 or 
ErbB4, leading to low level activation of these other RPTKs 
and consequent activation of Ras and the ERKI/ERK2 
pathway. 
Negative feed back is an important mechanism for signal 
dampening and desensitization. There are many exam- 
ples in which protein phosphorylation is used for this pur- 
pose, such as 13-adrenergic receptor phosphorylation by 
PKA. Negative feedback by an activated PK may be im- 
portant in MAPK pathways. Activated ERKI/ERK2 can 
phosphorylate SOS, Raf (Lee et al., 1992), MEKI/MEK2 
(Matsuda et al., 1993; Brunet et al., 1994; Gardner et al., 
1994), and MPK1 in vitro. Although this has no effect on 
MEKI/MEK2 and Raf activity, it could alter their subcellu- 
lar localization or sensitivity to PPs. ERKI/ERK2 phosphor- 
ylates SOS in the C-terminal domain that binds GRB2. 
Apparently this does not affect GRB2 binding, but may 
decrease the affinity of the GRB2-SOS complex for pTyr- 
containing proteins that hold it at the membrane. 
There are also numerous examples of cross-talk be- 
tween signaling pathways that involve protein phosphory- 
lation. In general, the greater the number of components 
present in a signal pathway, the more targets there are 
for cross-talk. Many PSKs and PTKs are positively or nega- 
tively regulated by serine or tyrosine phosphorylation or 
both, and the same is true of PSPs and PTPs, making 
them prime targets for cross-talk in pathways using PK 
cascades. For example, in NIH 3T3 fibroblasts, activation 
of the ERKI/ERK2 pathway is inhibited by activation of 
PKA (Burgering et al., 1993; Cook and McCormick, 1993; 
Graves et al., 1993; Sevetson et al., 1993; Wu et al., 1993) 
at the level of Rafl activation, possibly as a result of direct 
inhibitory phosphorylation of Rafl by PKA (Hafner et al., 
1994). However, PKA inhibition of ERKI/ERK2 activation 
is not universal. In PC12 cells, cAMP does not block NGF 
activation of ERKI/ERK2 and by itself stimulates ERKI/ 
ERK2 (Frodin et al., 1994; Vaillancourt et al., 1994). As 
in NIH 3T3 cells, cAMP inhibits NGF activation of Rafl or 
B-Raf, the main Raf isoform activated by NGF in PC12 
cells (Stephens et al., 1992; Jaiswal et al., 1994). Thus, 
cAMP activation of ERKI/ERK2 would have to be accom- 
plished by Raf-independent activation of a distinct 
MAPKKK, such as MEK kinase, which can also act on 
MEKI/MEK2 (Lange-Carter and Johnson, 1994). The dif- 
ferent effects of PKA activation on the ERKI/ERK2 path- 
way in fibroblasts and PC12 cells provide another illustra- 
tion of the fundamental cell type-specific differences in 
the detailed PK and PP 
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in the N-terminal transactivation domain. This phosphory- 
lation results in increased transactivating activity, without 
a significant effect on CREB DNA-binding activity. The 
extent of Ser-133 phosphorylation correlates directly with 
the rate of transcription of cAMP-responsive genes (Hagi- 
wara et al., 1993). Phosphorylation of Ser-133 promotes 
binding of the CREB-binding protein (CBP), a large protein 
with an activation domain that can interact with TFIIB 
(Chrivia et al., 1993; Kwok et al., 1994). CBP is thought o 
act as a coactivator linking CREB to the RNA polymerase 
II preinitiation complex. CREB itself can associate with 
TAF110 via the Q2 domain, in a phosphorylation-indepen- 
dent manner (Ferreri et al., 1994), meaning that there are 
two interactions between phospho-CREB and the tran- 
scription preinitiation complex. 
Although cAMP levels rise rapidly, phosphorylation of 
Ser-133 occurs relatively slowly after stimulation of PC12 
cells, not reaching a maximum until 30 min (Hagiwara et 
al., 1993). The kinetics of phosphorylation of CREB is 
much slower than for glycogen phosphorylase, in which 
maximal phosphorylation is detected within a few sec- 
onds. The rate of CREB phosphorylation is limited by the 
rate of entry of the PKA C subunit into the nucleus, which 
occurs over a 30 min period (Hagiwara et al., 1993). In 
unstimulated cells, much of CREB is in the chromatin com- 
partment bound to CREs in cAMP-responsive genes, but 
apparently is accessible for PKA C subunit phosphoryla- 
tion. Like most transcription factors, CREB is a low abun- 
dance protein, and PKA C subunit is in a slight molar ex- 
cess over CREB. However, CREB is a relatively inefficient 
substrate for PKA (Kr,, - 10 I~M), and this, together with 
other competing nuclear PKA substrates and the presence 
of PKI, a small protein inhibitor of PKA C subunit, may 
also limit the rate of CREB phosphorylation. Maximally, 
40°/0 of CREB can be phosphorylated, but this can be 
increased by overexpressing C subunit. 
Dephosphorylation of CREB occurs slowly over a few 
hours following stimulation and is accompanied by de- 
creased transcription of cAMP-responsive genes (Hagi- 
wara et al., 1992). In some cells, PP1 is the major PSP 
that dephosphorylates pSer-133. For instance, the main 
nuclear phospho-CREB PSP in PC12 cells is inhibited in 
vitro by I-1 and I-2, implicating PP1 (Hagiwara et al., 1992). 
Moreover, expression of the PP1 C subunit or microinjec- 
tion of purified protein reduces stimulated CREB activity, 
whereas the PP2A C subunit does not. Conversely, micro- 
injection of an expression plasmid for an activated mutant 
form of I-1 into rodent fibroblasts induces CREB Ser-133 
phosphorylation and augments CREB transcriptional ac- 
tivity following suboptimal PKA stimulation, whereas ex- 
pression of SV40 small t antigen, a PP2A inhibitor, does 
not affect CREB activation in stimulated or unstimulated 
fibroblasts (Alberts et al., 1994b). The ability of the mutant 
form of I-1 to induce CREB Ser-133 phosphorylation indi- 
cates that there is a basal rate of Ser-133 phosphorylation, 
which is normally held in check by PP1 activity (Alberts 
et al., 1994b). 
The data implicating PP1 as a phospho-CREB PSP in 
rodent cells are persuasive. However, in HepG2 human 
hepatoma cells and rat liver, the major phospho-CREB 
PSP activity in vitro was identified as PP2A, which dephos- 
pho~lated phospho-CREB 30-fold more efficiently than 
PP1 (Wadzinski et al., 1993). In addition, expression of 
SV40 small t antigen in HepG2 cells enhanced the effects 
of PKA stimulation on CRE reporter expression (Wheat et 
at., 1994). Perhaps the PSP responsible for CREB dephos- 
phorylation differs in different cell types, depending on the 
abundance of PP1 inhibitors and on relative levels of PP1 
and PP2A in the nucleus. In addition, PP5, a newly identi- 
fied member of the PPI/PP2A family, is localized in the 
nucleus, and this PSP could also play a role in phospho- 
CREB dephosphorylation (Chen et al., 1994). 
How then does CREB dephosphorylation proceed (Fig- 
ure 2)? In response to hormonal stimulation, cAMP synthe- 
sis is fairly rapidly attenuated by desensitization mecha- 
nisms acting at the receptor level, although active C 
subunit may persist in the nucleus. Dephosphorylation of 
CREB occurs even with continuous activation of adenylyl 
cyclase by forskolin, suggesting that down-regulation is 
an active process. One mechanism may involve PKI, a 
small nuclear PKA inhibitor, which facilitates export of the 
C subunit from the nucleus and thus down-regulates nu- 
clear C subunit activity (Fantozzi et al., 1994). As dis- 
cussed, there is a significant rate of CREB dephosphoryla- 
tion even in unstimulated cells. The absolute rate of CREB 
dephosphorylation has not been measured following PKA 
activation, but in cells where PP1 is involved, the rate of 
dephosphorylation may drop initially owing to I-1 phos- 
phorylation. However, C subunit activity could also in- 
crease the rate of dephosphorylation by phosphorylating 
NIPP1 and releasing PP1 C subunit. In summary, the de- 
cline in CREB phosphorylation upon stimulus withdrawal 
appears to be due to a slow decrease in nuclear C subunit 
activity, combined with increasing PSP activity. 
The regulation of CREB phosphorylation is complicated 
by the fact that other PKs can phosphorylate CREB at 
Ser-133 and provide cAMP-independent regulation. These 
include a novel NGF-induced Ras-dependent Ser-133 PK 
in PC12 cells, which may play a role in NGF-induced c-fos 
expression (Ginty et al., 1994), and the Ca2+-CaM-stimu - 
lated PKs CaMKII and CaMKIV (Dash et al., 1991 ; Sheng 
et al., 1991). In principle, phosphorylation by CaMKII or 
CaMKIV could explain how elevated intracellular Ca 2÷ in- 
duces CREB Ser-133 phosphorylation and activates CRE- 
regulated genes such as c-fos. However, Ca 2÷ does not 
induce c-fos expression in PC12 cells in the absence of 
functional PKA (Ginty et al., 1991). This could be because 
PKA-dependent phosphorylation of a second protein in 
this pathway, such as CBP, is needed, although microin- 
jected phospho-CREB is sufficient o drive CRE reporter 
gene expression in fibroblasts (Alberts et al., 1994a). In 
vivo, CaMKIV is likely to be the Ca2÷-stimulated PK in- 
volved in phosphorylating CREB, since expression of 
CaMKIV but not activated CaMKII stimulates CRE reporter 
gene expression (Matthews et al., 1994; Sun et al., 1994). 
Indeed, CaMKII phosphorylates not only the activating 
Ser-133 but also Ser-142, which inhibits CREB activity 
(Sun et al., 1994). This phosphorylation could be responsi- 
ble for down-regulating CRE-mediated transcription upon 
elevation of intracellular Ca 2+ in conjunction with PP2B, 
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Figure 3. Cyclin B-Cdc2 Regulation 
A schematic illustration of the PKs and PPs that regulate activation 
of cyclin B-Cdc2. PK1 and PK2 are unidentified PKs. 
which is activated by Ca2+-CaM and can dephosphorylate 
pSer-133. 
The Regulation of Cdc2: Positive and Negative 
Phosphorylation Feedback Loops 
An excellent example of the interplay between PKs and 
PPs is the regulation of Cdc2 activity during the cell cycle. 
Cdc2 is the founding member of a class of PSKs, the 
cyclin-dependent kinases (CDKs), whose activity is abso- 
lutely dependent on the association of specific regulatory 
subunits known as cyclins. Most CDKs function in conjunc- 
tion with their cognate cyclin partners to regulate cell cycle 
transitions (reviewed by Pines, 1993). In particular, cyclin 
A-Cdc2 and cyclin B-Cdc2 are required for the G2-M 
transition; activation of cyclin B-Cdc2 triggers entry into 
M phase, and inactivation of both cyclin-Cdc2 complexes 
is required for completion of mitosis (reviewed by King et 
al., 1994). 
Cdc2 is subject to both positive and negative regulation 
by phosphorylation (King et al., 1994) (Figure 3). Cdc2 PK 
activity requires phosphorylation by a second PK, known 
as CDK-activating kinase (CAK), at Thr-161, which lies in 
the catalytic domain at a position where many PKs have 
an activating phosphorylation site (reviewed by Solomon, 
1994). In the inactive Cdk2 monomer, there is a loop con- 
taining Thr-160 (equivalent to Thr-161) folded over the sub- 
strate-binding cleft, thus preventing substrate access. In 
combination with cyclin binding, phosphorylation of Thr- 
160 must move this loop away from the substrate cleft 
and anchor it in a new conformation. 
CAK is a nuclear PK in the CDK family in which Cdk7 
(MO15) is complexed to cyclin H (Solomon, 1994). Interest- 
ingly, CAK activity itself requires phosphorylation of Cdk7 
at Thr-176 (equivalent o Thr-161) by another PK, CAK- 
activating kinase (Labbe et al., 1994; Pooh et al., 1994), 
whose provenance is unknown. The significance of this 
PK cascade is currently unclear. All CDKs so far examined 
require phosphorylation at the activating threonine, and 
CAK is the only known PK that can carry out this phosphor- 
ylation (Solomon, 1994). CAK can only phosphorylate 
Cdc2 if it is associated with a cyclin partner, pThr-161 can 
be dephosphorylated by PP2A in vitro (Gould et al., 1991 ; 
Lee et al., 1991), and PP2A (INH) can prevent premature 
activation of cyclin B-Cdc2 in Xenopus oocyte extracts 
by blocking Thr-161 phosphorylation (Felix et al., 1990; 
Lee et al., 1991). However, the target for PP2A may not 
be pThr-161 itself, but rather a component required for 
Thr-161 phosphorylation, such as CAK, that would be inac- 
tivated by dephosphorylation of pThr-176 (Lee et al., 
1994). 
It is unclear whether Thr-161 phosphorylation is a target 
for regulation during interphase. Although low in GO, CAK 
activity is constant throughout the cell cycle in cultured 
mammalian cells (Poon et al., 1994; Tassan et al., 1994). 
Moreover, there is no evidence for changes in PP2A activ- 
ity during the cell cycle that could regulate Thr-161 phos- 
phorylation. Even if Thr-161 phosphorylation is not used 
as a Cdc2 regulatory mechanism, negative regulation of 
Cdk2 Thr-160 phosphorylation may play a part in the G1 
arrest induced by transforming rowth factor I} (TGFI~) in 
epithelial cells and by cAMP in macrophages (Kato et al., 
1994; Polyak et al., 1994). Both treatments elevate the 
level of free p27 CDK inhibitor, which binds to Cdk4 and 
Cdk2 cyclin complexes and not only inhibits CDK activity 
but also blocks CAK phosphorylation. 
Cyclin B-Cdc2 accumulates during the G2 phase, but 
is not active even though it is phosphorylated at Thr-161 
(reviewed by Dunphy, 1994; King et al., 1994). This is 
because Cdc2 is phosphorylated at Tyr-15 (and in metazo- 
ans as well on Thr-14) in the ATP-binding domain, and 
these phosphates inhibit Cdc2 activity. Like Thr-161 phos- 
phorylation, Tyr-15 phosphorylation only occurs if Cdc2 
is bound to cyclin B, thus providing a mechanism for imme- 
diate inactivation of cyclin B-Cdc2 complexes as they form 
following cyclin B synthesis during G2. This is critical be- 
cause premature activation of cyclin B-Cdc2 would result 
in a mitotic catastrophe. Tyr-15 is phosphorylated by mem- 
bers of a PK family that includes Wee1 and Mikl (Feath- 
erstone and Russell, 1991; Parker et al., 1992), first iden- 
tified through genetic analysis as partially redundant 
negative regulators of Cdc2 in Schizosaccharomyces 
pombe. A single Weel/Mik-related PK has been identified 
in mammals (Igarashi et al., 1991), in Xenopus, and in 
budding yeast (Booher et al., 1993). However, the verte- 
brate Weel-like PKs are not very closely related to the 
yeast enzymes, and it is unclear whether these are true 
homologs, even though human WEE1 phosphorylates 
Tyr-15 and complements a wee1 mutation in S. pombe 
(Igarashi et al., 1991). The Thro14 PK is unknown, but in 
Xenopus there is a distinct membrane-associated PK that 
can phosphorylate both Thr-14 and Tyr-15 (Atherton- 
Fessler et al., 1994; Kornbluth et al., 1994). 
It is not immediately obvious why both Thr-14 and Tyr-15 
are phosphorylated in metazoans, since in fission yeast 
Tyr-15 phosphorylation is sufficient o provide normal cell 
cycle regulation. The mechanism of Cdc2 inhibition is not 
fully understood, but in vertebrates Cdc2 mutant studies 
indicate that phosphorylation of either Thr-14 or Tyr-15 
provides a significant degree of negative regulation (Krek 
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and Nigg, 1991 ; Norbury et al., 1991 ; Pickham et al., 1992). 
In addition, overexpression of a truncated form of human 
WEE1, which can only phosphorylate Tyr-15, is sufficient 
to block HeLa cells in G2 (McGowan and Russell, 1993). 
It is possible that there are distinct pathways activating a 
Tyr-15 PK and a Thr-14/Tyr-15 PK as part of G2 checkpoint 
controls in vertebrates. In addition, the twin phosphates 
may be important for properly coordinated activation by 
Cdc25 (see below) and may also prevent dephosphoryla- 
tion by conventional PTPs. 
In fission yeast, Wee1 is negatively regulated by another 
PSK, Niml (Cdrl), which phosphorylates the C-terminal 
Wee1 catalytic domain and inhibits activity (Coleman et 
al., 1993; Parker et al., 1993; Wu and Russell, 1993). A 
second PSK, Wisl, may also play a role in negative regula- 
tion of Wee1 in S. pombe; as for Niml, overexpression of 
Wisl induces premature mitosis, and loss of Wisl function 
lengthens G2 (Warbrick and Fantes, 1991). So far, Niml 
and Wisl homologs have not been identified in metazo- 
ans; human WEE1 is phosphorylated in interphase, but 
these phosphorylations do not appear to regulate catalytic 
activity. Xenopus Wee1 (Tang et al., 1993) and human 
WEE1 are negatively regulated by hyperphosphorylation 
in M phase, but this appears to be due to a PK other than 
cyclin B-Cdc2. 
The major protein PP that dephosphorylates the Cdc2 
inhibitory sites is Cdc25 (Dunphy, 1994; King et al., 1994). 
Cdc25, which was initially identified as a positive regulator 
of Cdc2 in fission yeast, is distantly related to the main 
PTP family. Cdc25 is a dual specificity PP that can de- 
phosphorylate both pThr-14 and pTyr-15. In mammals, 
there are three Cdc25s (Cdc25A, Cdc25B, and Cdc25C) 
closely related in their C-terminal catalytic domains, but 
only weakly related in their N-terminal "regulatory" do- 
mains (Galaktionov and Beach, 1991). The three Cdc25s 
are regulated during the cell cycle and appear to function 
at different imes: Cdc25A is required for the G1-S transi- 
tion (Hoffman et al., 1994; Jinno et al., 1994), whereas 
Cdc25C is needed for the G2-M transition (Galaktionov 
and Beach, 1991; Millar et al., 1991); the execution point 
for Cdc25B is unknown. Cdc25A levels stay constant in 
the cell cycle, but its activity rises at the GI-S transition 
owing to phosphorylation by cyclin E-Cdk2 (Hoffman et 
al., 1994). Cdc25C is also present at constant levels 
throughout he cycle (Millar et al., 1991) and is activated 
in M phase by phosphorylation at a series of sites in the 
N-terminal regulatory domain (Izumi et al., 1992; Kumagai 
and Dunphy, 1992; Hoffman et al., 1993; Izumi and Mailer, 
1993). This phosphorylation is mediated by cyclin B-Cdc2 
and results in a 3- to 5-fold increase in Cdc25 activity. 
Cdc25 preferentially dephosphorylates doubly phosphory- 
lated Cdc2 (Sebastian et al., 1993), a feature also noted 
for the MKPl-related dual specificity PPs, and this could 
be a rationale for having two sites phosphorylated in Cdc2. 
In fission yeast, there is another PTP, Pyp3, that can 
dephosphorylate Tyr-15 (Millar et al., 1992a). Pyp3, which 
was identified as a high copy suppressor of a cdc25 muta- 
tion, is essential in a cdc25 mutant strain, and loss of Pyp3 
function results in a lengthening of G2, suggesting that 
Pyp3 acts cooperatively with Cdc25. However, it is unclear 
whether there are equivalent PTPs in other organisms. 
Interestingly, two other fission yeast PTPs, Pypl and 
Pyp2, with partly overlapping functions, play a negative 
role at the G2-M transition by promoting the inhibitory 
Wee1 pathway through an unknown mechanism (Millar et 
al., 1992b). 
The importance of PSPs in preventing premature entry 
into mitosis is underscored by the fact that OA treatment 
activates Cdc2 and induces an M phase state in many 
types of eukaryotic cells. However, it is unclear whether 
PP1 or PP2A or both are the critical target(s) for OA- 
induced mitosis. In starfish oocytes, inhibition of both PP1 
and PP2A is required to trigger entry into M phase (Picard 
et al., 1989). In cycling Xenopus egg extracts, PP1 activity 
oscillates; activity is high in interphase, falls just before 
M phase, coincident with the onset of Cdc2 activation, and 
then rises in M phase (Walker et al., 1992). In this system, 
addition of I-2 induces premature mitosis, whereas addi- 
tion of PP1 C subunit lengthens interphase. However, in 
an Xenopus egg $100 extract, Cdc2 can be activated by 
OA at a concentration in which only PP2A is inhibited (Felix 
et al., 1990). In mammalian cells, PP1 C subunit moves 
into the nucleus during G2 phase (Fernandez et al., 1992), 
and I-2 levels fluctuate during the cycle peaking at S and 
M phases (Brautigan et al., 1990). Microinjection of anti-l-2 
antibodies into REF-52 rat embryo fibroblasts induces a 
pseudomitotic response (Brautigan et al., 1990), again 
consistent with PP1 playing a role in repressing Cdc2 acti- 
vation. Finally, in fission yeast, overexpression of PP2A 
C subunit arrests cells in interphase, and genetic evidence 
indicates that PP2A C subunit negatively regulates entry 
into mitosis (Kinoshita et al., 1993). However, overexpres- 
sion of PP1 C subunit also delays entry into M phase, at 
least when Wee1 and Cdc25 are inactive (Booher and 
Beach, 1989). One explanation for the conflicting results 
is that PP1 and PP2A act on different targets to prevent 
Cdc2 activation and that PP1 and PP2A are more or less 
important depending on the relative contributions of the 
different pathways to Cdc2 activation. For instance, PP2A 
may act to inhibit Thr-161 phosphorylation, whereas PP1 
may prevent Cdc25C activation. 
Cyclin B-Cdc2 accumulates in the inactive state in G2 
and is activated explosively at the G2-M transition. Given 
what we know about the PKs and PPs that regulate Cdc2 
activity, how is this orchestrated (Figure 3)? Although the 
status of Thr-161 phosphorylation could play a role, 
ultimately itis the balance between Thr-14/Tyr-15 PK and 
PP activity that is the critical factor (Dunphy, 1994). 
The feedback systems responsive to unreplicated DNA 
and unrepaired DNA damage that act to regulate the 
timing of cyclin B-Cdc2 activation work at least in part 
through Thr-14/Tyr-15 phosphorylation. The precise feed- 
back mechanisms are unknown, but in fission yeast, mi- 
totic delay induced by unreplicated DNA requires Cdc25 
but not Wee1, whereas the delay induced by DNA damage 
apparently does not require either Wee1 or Cdc25 (Rowley 
et al., 1992; Barbet and Carr, 1993). In Xenopus egg ex- 
tracts, unreplicated DNA has been reported to increase 
the activity of a Tyr-15 PK, without apparently affecting the 
activity of Cdc25C (Smythe and Newport, 1992). Cdc25 
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activation involves a positive feedback loop in which as 
cyclin B-Cdc2 is activated, it phosphorylates and activates 
more Cdc25C (Izumi et al., 1992; Kumagai and Dunphy, 
1992; Hoffman et al., 1993; Izumi and Mailer, 1993). How- 
ever, activation of the first molecules of Cdc25C may re- 
quire a triggering phosphorylation event by another PK 
(Izumi and Mailer, 1993). In addition, inhibition of Wee1 
activity could be the initial event allowing basal Cdc25C 
activity to activate a few molecules of cyclin B-Cdc2. 
Wee1 activity is inhibited by phosphorylation during M 
phase (Kumagai and Dunphy, 1992), but it is not clear 
what PK is involved and whether this is a primary event 
or rather whether it reflects the Cdc2-dependent activation 
of a mitotic PK. In either case, the inactivation of Wee1 
is presumably important to ensure that Cdc2 remains 
maximally activated during M phase. Whatever the precise 
mechanism, once the system has been set in motion, then 
very rapidly all Cdc25C molecules will be activated 
through positive feedback and Cdc2 will be fully dephos- 
phorylated, as is observed experimentally. 
In summary, the sophisticated reg~Jlatory cycles govern- 
ing Cdc2 activation at the G2-M transition rely heavily on 
the balance between the PKs and PPs that act on Cdc2 
and on its regulators. Cyclin B-Cdc2 itself plays a role in 
a positive feedback loop activating Cdc25C and may also 
be involved in a negative feedback loop inactivating Wee1. 
Similar regulatory cycles exist in vertebrate cells for other 
interphase CDKs, which are inhibited by Thr-14/Tyr-15 
phosphorylation and activated by Cdc25 dephosphoryla- 
tion, but much less is known about the proteins involved. 
Finally, it should also be borne in mind that, although the 
major players are the same, the precise details of Cdc2 
regulation often differ among organisms and in different 
types of cell cycle. For instance, negative regulatory phos- 
phorylation of Thr-14/Tyr-15 is not used in the first 13 divi- 
sions in Drosophila embryos, and this mechanism is not 
activated until the cell cycle acquires a G2 phase at cycle 
14, at which point cyclic regulation of the Drosophila 
Cdc25, called string, becomes a paramount cell cycle reg- 
ulator (Edgar et al., 1994). Likewise, Tyr-15 phosphoryla- 
tion does not play an essential role in the budding yeast 
cell cycle under normal growth conditions (Amon et al., 
1992; Sorger and Murray, 1992). 
Perspectives 
Many recent studies have underscored the physiological 
importance of protein phosphorylation etworks in signal 
transduction. PK cascades, which are commonly the basis 
of such networks, and other types of transcytoplasmic sig- 
naling pathways, such as the JAK/STAT system, often 
use families of closely related PKs, yet there is limited 
cross-talk even at the level of targets. A major question 
for the future is to determine how specificity is achieved. 
One possibility is that scaffolding proteins assemble ap- 
propriate PKs into a single complex. Such complexes 
might also include cognate PPs. Substrate specificity can 
also be achieved through secondary binding sites for the 
substrates on PK catalytic or regulatory domains. Another 
emerging specificity mechanism is signal compartmental- 
ization, in which receptors, receptor targets, and down- 
stream signaling molecules, including PKs and PPs, are 
localized through a combination of targeting domains and 
protein-protein interactions, allowing specific transloca- 
tion of signaling components either within the cytoplasm 
or via regulated membrane vesicle movement. 
The fact that the activity of PPs can be regulated raises 
the possibility that cellular responses to some external 
stimuli might result from direct activation or inhibition of 
PPs, rather than through PKs. External stimuli such as 
insulin can induce protein dephosphorylation. However, 
in this case, dephosphorylation is apparently an indirect 
effect of insulin activation of the MAPK cascade leading 
to activation of PPI. Are there authenticated instances in 
which activation of a PP is the primary event in signal 
transduction? An obvious example is PP2B, which is es- 
sential for T cell activation and which is activated by in- 
creased intracellular Ca 2÷. However, the targets for PP2B, 
whose dephosphorylation is needed for the activation of 
gene expression in T cells, are not known. Another possi- 
ble example is provided by the RPTPs, whose activity can 
in principle be modulated by the binding of an extracellular 
ligand. No bona fide ligand has been identified for any of 
these RPTPs, and therefore it is not known whether ligand 
binding can modulate PTP activity. Nevertheless, it is likely 
that systems will emerge in which PP activity is regulated 
by PK-independent signals that either affect activity di- 
rectly or else affect PP distribution in the cells. An investi- 
gation of the roles of PTPs in regulating signaling via tyro- 
sine phosphorylation will be a major emphasis and should 
uncover the reason why closely related PTPs like PTP1C 
and PTP1D can have opposing effects on mitogenic sig- 
naling. The possibility that there are specific PTP and PTK 
inhibitors, as is the case for PSPs and PSKs, needs to be 
explored. 
The complexity of protein phosphorylation etworks is 
growing, and elucidating the outputs of such networks be- 
comes an increasingly daunting prospect, especially given 
the cell-type specificities and the fact that intracellular 
events may be compartmentalized inthe cytoplasm. There 
is clearly a real need for development of algorithms that 
can predict the output of protein phosphorylation net- 
works. 
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